Talk:Familial amyloid polyneuropathy

message: Is 'familial amyloid polyneuropathy' the same disease as 'familial amyloid neuropathy'? If yes, the articles should be merged. If no, some distinction should be made in the articles, at least with a hatnote. --Eleassar my talk 10:03, 13 June 2010 (UTC)
thread_title: Familial amyloid neuropathy

message: maybe useful to develop some content from these:
* Obici L, Merlini G. An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opin Investig Drugs. 2014 Sep;23(9):1239-51. doi: 10.1517/13543784.2014.922541. Epub 2014 Jul 8. Review.  
* Plante-Bordeneuve V. Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol. 2014 Jun;261(6):1227-33. doi: 10.1007/s00415-014-7373-0. Epub 2014 Jun 3. Review. 
* Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014 Jun;39(3):225-33. doi: 10.1111/jcpt.12145. Review. 
* Yin J, et al Chinese familial transthyretin amyloidosis with vitreous involvement is associated with the transthyretin mutation Gly83Arg: a case report and literature review. Amyloid. 2014 Jun;21(2):140-2. doi: 10.3109/13506129.2014.892871. Epub 2014 Mar 6. Review. 
* Adams D, et al. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep. 2014 Mar;14(3):435. doi: 10.1007/s11910-013-0435-3. Review. 
* Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep. 2014 Mar;11(1):50-7. doi: 10.1007/s11897-013-0182-4. Review.  
* Aljaroudi WA et al. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol. 2014 Apr;21(2):271-83. doi: 10.1007/s12350-013-9800-5. Review. 
* Mohty D, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013 Oct;106(10):528-40. doi: 10.1016/j.acvd.2013.06.051. Epub 2013 Sep 23. Review. 
* Planté-Bordeneuve V, Kerschen P. Transthyretin familial amyloid polyneuropathy. Handb Clin Neurol. 2013;115:643-58. doi: 10.1016/B978-0-444-52902-2.00038-2. Review.  
* Ando Y, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 Feb 20;8:31. doi: 10.1186/1750-1172-8-31. Review. 
yep Jytdog (talk) 18:00, 23 March 2015 (UTC)
thread_title:  sources 

message: The lead section says that "FAP is distinct from senile systemic amyloidosis", yet Senile systemic amyloidosis redirects to this article. Why not separate articles about the two, particularly since (despite the redirect) there is nothing in this article, other than the the lead-section sentence, where senile systemic amyloidosis is mentioned? -- John Broughton   (♫♫) 18:39, 9 June 2015 (UTC)
thread_title:  Senile systemic amyloidosis? 

message: at Wikipedia_talk:Identifying_reliable_sources_(medicine)#Time_to_play_the_fake_secondary_source_game Jytdog (talk) 05:20, 13 September 2018 (UTC)
thread_title:  Sort of a discussion 

message: And this article still has no informaton about the NEJM study, because you wouldn't let me add it last September. Happy with yourselves? I'm just checking in to see. SBHarris 04:51, 23 July 2019 (UTC)
thread_title:  Well, the drug tafamidis was just approved by the FDA for treatment of ATTR cardiomyopathy, in May. Jytdog has been banned from Wikipedia.